Accedi

Novocure Ltd., Haifa, Israel

2 ARTICLES PUBLISHED IN JoVE

Cancer Research

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)

Yaara Porat¹, Moshe Giladi¹, Rosa S. Schneiderman¹, Roni Blat¹, Anna Shteingauz¹, Einav Zeevi¹, Mijal Munster¹, Tali Voloshin¹, Noa Kaynan¹, Orna Tal¹, Eilon D. Kirson², Uri Weinberg³, Yoram Palti²

¹Preclinical Research Department, Novocure Ltd., Haifa, Israel, ²Novocure Ltd., Haifa, Israel, ³Novocure GmbH, Lucerne, Switzerland

Tumor Treating Fields (TTFields) are an effective anti-tumor treatment modality delivered via the continuous, noninvasive application of low-intensity, intermediate-frequency, alternating electric fields. TTFields application to cell lines using a TTFields in vitro application system allows for the determination of the optimal frequency that leads to the highest reduction in cell counts.

Immunology and Infection

Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli

Ilan Edri^*1, Michal Goldenberg^*1, Michal Lisnyansky², Roi Strulovich², Hadas Newman^1,3, Anat Loewenstein^1,3, Daniel Khananshvili², Moshe Giladi^2,4, Yoni Haitin²

¹Sackler Faculty of Medicine, Tel Aviv University, ²Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, ³Department of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, ⁴Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University

A simple protocol for overexpression and purification of codon-optimized, human cis-prenyltransferase, under non-denaturing conditions, from Escherichia coli, is described, along with an enzymatic activity assay. This protocol can be generalized for production of other cis- prenyltransferase proteins in quantity and quality suitable for mechanistic studies.